Moderna wants to vaccinate children under 5 against Kovid-19 in the United States; Denmark has stopped vaccination activities

Conflict in the first place always exists in human life. Just think of the space race during the Cold War and now, 65 years later, the race to make a vaccine against it Covid-19 As quickly and efficiently as possible. The Modern May not be the first Vaccine Definitely allowed, but wants to be available first for this Children.

Has requested approval from the company Food and drug administration (The FDAUS regulatory agency) to use its coronavirus vaccine for children aged six months to five years.

This makes it one of the first manufacturers to apply to the FDA. Until then, it was the only vaccine approved for children Pfizer-BioNTech, published for children ages 5 to 11 and adolescents ages 12 to 17.

Modern vaccine against Kovid-19 for children

Unlike Pfizer, Moderna’s vaccine is only approved for adults. That is from the age of 18 years. The drug manufacturer’s new application also includes an application for vaccine approval for children aged 6 to 11 and 12 to 17 years.

According to a company spokesman, information on the order will be sent to regulatory agencies by May 9.

At Tuesday’s Senate hearing, Peter Marks, the FDA’s vaccine regulator, indicated that the agency could consider a modern application for anyone under the age of 18.

“Some applications are complex because they are relatively large and cover a larger portion of the pediatric population than others,” Marx said.

Vaccine race between Moderna and Pfizer

Moderna and Pfizer-BioNTech have been in the race to create safe doses for young children since 2021. The development of vaccines puts increasing pressure on U.S. regulators to approve a pediatric vaccine.

Moderna recommends a two-dose regimen for children aged six months to five years, each dose equal to a quarter of the normal adult dose.

Meanwhile, Pfizer and BioNTech are developing a three-dose method for children aged six months to four years, with one-tenth dose for adults.

It is noteworthy that Pfizer has not yet applied for FDA approval However, the market expects the company to send orders to the agency soon.

In February, the FDA sought to expedite the approval of the Pfizer vaccine for children under 5 years of age by releasing the first two doses of the vaccine. However, the drug manufacturer decided to suspend the request and wait for new data from the third dose, as the results of the initial two doses were not good enough. According to Pfizer CEO Albert Borla, the first two doses were only 30% to 40% effective.

FDA review of Pfizer and Moderna

The FDA has promised to expedite the process of approving vaccines for children under the age of six if manufacturers regularly submit complete application forms, including all application data.

Anthony Fawcett, the White House’s chief medical adviser, suggested in an interview last week that the FDA wants to review Moderna and Pfizer’s data at the same time.

According to Fawcett, the agency’s goal is to compare data directly from each vaccine for young children in order to “confuse people” about its effectiveness.

But Moderna’s chief medical officer said he expected the FDA to review Moderna’s vaccine for three people under the age of 18 – six months to five years, five to 11 and 12 to 17 – at once.

An incomplete treatment is required

Moderna Medical Director Paul Burton highlighted in an interview that there is an “irreversible medical need” for the younger population and he hopes that the Food and Drug Administration “will evaluate the data carefully and accurately and will not withhold it.”

Parents of children under the age of five have been waiting for months for a pediatric vaccine, as they are the only part of the population that is not yet eligible for the covid vaccine.

“There are many parents who are desperate to get vaccinated for many reasons. And we’re almost there. I think these children need a vaccine. On the other hand, I acknowledge that this is a critical situation for the FDA, “said Sean O’Leary, vice chairman of the Infectious Diseases Committee of the American Academy of Pediatrics.

However, U.S. regulators are not expected to review Moderna’s application until June, as officials have announced that the data will be reviewed by an external advisory panel of agency experts before any approval.

Effectiveness of vaccine against Kovid-19 in children

The effectiveness of Moderna vaccine in children varies depending on the age of the patients.

According to the company, among children under two years of age, the vaccine against omikron variant infection was about 51% effective.

Already in children between the ages of two and five, efficacy has reached about 37%.

According to Paul Burton, medical director of Pharmaceuticals, the dose of pediatric vaccine is similar to the protection given by adults in two doses.

According to Burton, children who receive both doses should have a higher level of protection against developing more severe cases, with 90% efficacy, even though the dose is lower than when Moderna first announced the vaccine.

Although adults showed about 1,000 antibody units after two doses, with at least 70% protection against serious illness, the Moderna study reported between 1,400 and 1,800 antibody units after children completed their vaccination schedule.

“What we do know is that these antibody levels are going to translate into very high protection against serious illness and hospitalization,” Burton said.

The end of the epidemic in the Kingdom of Denmark?

Especially after the carnival here, we hear many authorities say that the epidemic is not over. But that is not happening in Denmark.

The country has become the first nation to stop vaccinating against Kovid-19, and its rationale is correct: the virus is under control.

“Spring has come, vaccination coverage in the Danish population is high and the epidemic has reversed,” the Danish health authorities said.

However, this does not mean that vaccination will stop. Dosage areas against Covid-19 will remain open across the country.

The decision by Denmark’s National Health Council is to end the massive effort this season by stopping people from being invited to get vaccinated on May 15.

All Danes who wish to complete their immunization schedule can be vaccinated, and health authorities even advise citizens to complete the immunization course.

“We have good control of the epidemic, which seems to be declining. Admission fee [aos hospitais] Stable and we hope they will drop soon. Therefore, we are carrying out a mass vaccination campaign against COVID-19, “said Bolett Soberg, manager of the National Health Council of Denmark.

Denmark’s coronavirus vaccination campaign began in December 2020, more than 4.8 million people were vaccinated and about 3.6 million people were vaccinated against the virus.

Health authorities have highlighted the need to resume vaccination against Kovid-19 in September, when autumn will begin in Denmark, as the virus continues to change.

* Including information from the New York Times and CNBC

Leave a Comment

Your email address will not be published.